Edgewise Therapeutics reports Q1 EPS (43c), consensus (42c)

Cash, cash equivalents and marketable securities were approximately $436.4M as of March 31. “We’re seeing strong progress across our skeletal and cardiac muscle programs,” said CEO Kevin Koch. “Most recently, we announced positive top-line results from CIRRUS-HCM and completed a $200M offering enabling the execution of our near and long-term goals. Our goals include commercial readiness for a potential U.S. approval of sevasemten in Becker, advancement of a Phase 3 trial in Duchenne, a Phase 3 program in HCM and our ongoing research and development activities. We anticipate several key milestones this year in both our sevasemten and EDG-7500 programs.”